Company intelligence / Profile preview
UroGen Pharma
Princeton, New Jersey, USAurogen.com ↗
- Ownership
- Public · URGN
- Employees
- ~201
- Development stage
- Other
01
Overview
UroGen’s lead product, Jelmyto® (mitomycin) for pyelocalyceal solution, was approved by the FDA in 2020 as the first non-surgical therapy for LG‑UTUC. The company’s second lead asset, UGN‑102, has shown an 80.6% duration of response at 18 months in Phase 3 ENVISION trial data for recurrent LG IR-NMIBC and has a rolling NDA submission underway with potential FDA decision expected as early as Q1 2025[3][7]. Other programs are advancing through clinical development.
- Therapeutic areas
- Oncology
- Modalities
- small molecules (notably mitomycin)hydrogel-based drug delivery
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
medac GmbH (next-gen mitomycin formulations)[9]Pharmakon Advisors LP (financing partnership)[7]
04
Financials
- Market cap
- $1.3B
- Total revenue
- $109.8M
- Enterprise value
- $1.4B
Beyond the preview
Go deeper on UroGen Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UroGen Pharma.